1. Home
  2. MIST vs NYXH Comparison

MIST vs NYXH Comparison

Compare MIST & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Milestone Pharmaceuticals Inc.

MIST

Milestone Pharmaceuticals Inc.

HOLD

Current Price

$0.36

Market Cap

95.3M

Sector

Health Care

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

SELL

Current Price

$0.89

Market Cap

91.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MIST
NYXH
Founded
2003
2009
Country
Canada
Belgium
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.3M
91.6M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
MIST
NYXH
Price
$0.36
$0.89
Analyst Decision
Strong Buy
Buy
Analyst Count
7
4
Target Price
★ $4.14
$2.80
AVG Volume (30 Days)
★ 1.3M
264.2K
Earning Date
11-13-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$210.30
$234.49
Revenue Next Year
$251.88
$98.07
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.80
52 Week High
$3.06
$5.39

Technical Indicators

Market Signals
Indicator
MIST
NYXH
Relative Strength Index (RSI) 24.59 36.73
Support Level N/A $0.80
Resistance Level $0.84 $0.97
Average True Range (ATR) 0.08 0.05
MACD -0.02 0.02
Stochastic Oscillator 0.00 51.15

Price Performance

Historical Comparison
MIST
NYXH

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: